ES2562416T3 - Régimen de dosificación de derivados de sulfuro de diarilo - Google Patents

Régimen de dosificación de derivados de sulfuro de diarilo Download PDF

Info

Publication number
ES2562416T3
ES2562416T3 ES11720419.8T ES11720419T ES2562416T3 ES 2562416 T3 ES2562416 T3 ES 2562416T3 ES 11720419 T ES11720419 T ES 11720419T ES 2562416 T3 ES2562416 T3 ES 2562416T3
Authority
ES
Spain
Prior art keywords
compound
solvate
hydrate
amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11720419.8T
Other languages
English (en)
Spanish (es)
Inventor
Peter Gergely
Eric Legangneux
Erik Wallstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2562416T3 publication Critical patent/ES2562416T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES11720419.8T 2010-05-06 2011-05-05 Régimen de dosificación de derivados de sulfuro de diarilo Active ES2562416T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10162082 2010-05-06
EP10162082 2010-05-06
PCT/EP2011/057210 WO2011138398A1 (en) 2010-05-06 2011-05-05 Dosage regimen of diaryl sulfide derivatives

Publications (1)

Publication Number Publication Date
ES2562416T3 true ES2562416T3 (es) 2016-03-04

Family

ID=42236590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11720419.8T Active ES2562416T3 (es) 2010-05-06 2011-05-05 Régimen de dosificación de derivados de sulfuro de diarilo

Country Status (12)

Country Link
US (4) US20130210924A1 (https=)
EP (1) EP2566473B1 (https=)
JP (3) JP2013525469A (https=)
KR (1) KR20130098885A (https=)
CN (2) CN106309416A (https=)
AU (1) AU2011249789B2 (https=)
BR (1) BR112012028248A2 (https=)
CA (1) CA2794607A1 (https=)
EA (1) EA201201515A1 (https=)
ES (1) ES2562416T3 (https=)
MX (1) MX2012012925A (https=)
WO (1) WO2011138398A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
BR112015019197A2 (pt) 2013-02-20 2017-07-18 Kyorin Seiyaku Kk tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
JP4571497B2 (ja) * 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
ES2529724T3 (es) * 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
PL2278960T5 (pl) * 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist

Also Published As

Publication number Publication date
WO2011138398A1 (en) 2011-11-10
AU2011249789B2 (en) 2015-03-19
US20170119702A1 (en) 2017-05-04
US20130210924A1 (en) 2013-08-15
JP6290963B2 (ja) 2018-03-07
CA2794607A1 (en) 2011-11-10
EA201201515A1 (ru) 2013-08-30
US20140336265A1 (en) 2014-11-13
MX2012012925A (es) 2012-12-17
BR112012028248A2 (pt) 2016-08-02
EP2566473B1 (en) 2016-01-06
JP2016183159A (ja) 2016-10-20
JP2018100280A (ja) 2018-06-28
CN102917698A (zh) 2013-02-06
CN106309416A (zh) 2017-01-11
JP2013525469A (ja) 2013-06-20
KR20130098885A (ko) 2013-09-05
AU2011249789A1 (en) 2012-12-13
JP6615247B2 (ja) 2019-12-04
EP2566473A1 (en) 2013-03-13
US20180161290A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
MX2022003984A (es) Compuestos heterociclicos antivirales.
CL2023001738A1 (es) Inhibidores de prmt5
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
ES2760607T3 (es) Régimen de dosificación para un agonista del receptor s1p
ECSP045501A (es) Moduladores de receptores nucleares de hormonas esteroideas triciclicos
RU2011129856A (ru) Схема приема агониста рецептора s1p
JP2012180381A5 (https=)
AR061584A1 (es) Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
ES2562416T3 (es) Régimen de dosificación de derivados de sulfuro de diarilo
AR129003A1 (es) Compuestos heterocíclicos antivirales
MX2014002663A (es) Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
JP2017516829A5 (https=)
Caraceni et al. Gabapentin for breakthrough pain due to bone metastases
BRPI0610663A2 (pt) uso terapêutico de nefopam e seus análogos
AR088453A1 (es) Regimen de dosificacion del agonista o modulador del receptor de s1p